In addition to IMIDs (immunomodulatory agents) and PIs (proteasome inhibitors), daratumumab, an anti-CD38 antibody initially approved for relapsed/refractory patients, is now moving into the frontline setting for newly diagnosed multiple myeloma, therefore adding a third gold standard in the newly diagnosed multiple myeloma therapeutic paradigm [1, 2]. The gene discussed is CD38; the disease is AL amyloidosis.